Female CB17-SCID mice (6–8 weeks of age) were purchased from Vital River Laboratory Animal Technology Inc. (Beijing, China). All animal experiments were carried out under protocols approved by the Institutional Animal Care and Use Committee of the Medical College of Jinan University. An amount of 2 × 106 BaF3-CD74-TRKA-G667C cells were injected subcutaneously in the right flank of the SCID mice. When the mean tumor volume reached 100–200 mm3, mice were randomly grouped based on the tumor volume. JND4135 was dissolved with the solution containing 2% DMSO, 20% Cremophor, 8% absolute alcohol and 70% normal saline. The animals were treated with JND4135 for 12 consecutive days once daily by oral gavage with 20 mg/Kg (n = 6) or 40 mg/Kg (n = 6) of JND4135 and vehicle (n = 6), respectively. Tumor volume and body weight were monitored once every two days. Tumor volume was calculated as L×W2/2, where L is the length and W the width of the tumor. Tumor volumes were compared using one-way ANOVA with post hoc intergroup comparison using the Tukey test.
Cb17 scid female mice
Manufactured by Charles River Laboratories
Sourced in China
The CB17-SCID female mice are a laboratory animal model characterized by a severe combined immunodeficiency (SCID) phenotype. They lack functional T and B cells, which makes them useful for a variety of research applications where a severely compromised immune system is desired.
Automatically generated - may contain errors
Lab products found in correlation
Rpmi 1640 medium, by Thermo Fisher Scientific (1 mentions)
Hi fbs, by Thermo Fisher Scientific (1 mentions)
Female nod scid mice, by Charles River Laboratories (1 mentions)
Dulbecco modified eagle medium (dmem), by Thermo Fisher Scientific (1 mentions)
Brilliant violet421 anti mouse cd45, by BioLegend (1 mentions)
Gfr matrigel, by Corning (1 mentions)
Doxycycline, by Merck Group (1 mentions)
Cd1 nude, by Charles River Laboratories (1 mentions)
9 protocols using cb17 scid female mice
1
Evaluation of JND4135 in SCID Mice
2
Cell Lines and Animal Model for Cancer Research
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The human breast cancer cell lines MCF7, SKOV3, and SKBR3; the colon cancer cell line LS174T; and the Chinese hamster ovary cell line CHO were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). MCF7, SKBR-3, and SKOV3 cells were cultured in DMEM (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) with 10% heat-inactivated fetal bovine serum (HI-FBS; Gibco, Thermo Fisher Scientific) and 1% penicillin/streptomycin. LS174T and CHO cells were cultured in RPMI-1640 medium (Gibco, Thermo Fisher Scientific) with 10% HI-FBS (Gibco, Thermo Fisher Scientific) and 1% penicillin/streptomycin. All cells were incubated at 37°C in a humidified incubator with 5% CO2.
Female NOD/SCID mice and female CB-17 SCID mice were purchased from Vital River Laboratory Animal Technology (Beijing, China). The animals were acclimated for 1 week prior to experiment. The mice were housed in a temperature- and humidity-controlled environment with a controlled light-dark cycle (12-12 h). Animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee, Sun Yat-Sen University.
Female NOD/SCID mice and female CB-17 SCID mice were purchased from Vital River Laboratory Animal Technology (Beijing, China). The animals were acclimated for 1 week prior to experiment. The mice were housed in a temperature- and humidity-controlled environment with a controlled light-dark cycle (12-12 h). Animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee, Sun Yat-Sen University.
3
Synergistic Effects of Antibody Combination in Myeloma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Example 6
This example describes the synergistic properties that can be observed when a 2.3D11 derived antibody is combined with an anti-CD38 opsonizing antibody in a murine model of multiple myeloma.
8-12 week old CB.17 SCID female mice (Charles River) were injected subcutaneously with 1×107 H929 tumor cells in 50% Matrigel in the right flank. Cell injection volume was 0.1 mL/mouse. When tumors reached an average size of 100-150 mm3, animals were randomized to control or treatment. Treatment groups included 2.3D11 IgG4 at 30 μg/mouse (injected intraperitoneally (i.p.) three times per week for 3 weeks), daratumumab at 10 μg/mouse (injected i.p. at a single dose), and a combination of the two antibodies. Tumor volumes were measured twice weekly with a caliper using the formula (length*width2*0.52). The results are show in
4
Orthotopic Mammary Tumor Xenograft Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
MDA-MB-231-LIN7A cells (3 × 106 cells/mouse) were orthotopically injected into the mammary fat-pad of CB17-SCID female mice (7 weeks of age, Charles River Laboratories, L’Arbresle, France) and the tumor growth was followed for 15 weeks.
The care and use of animals were carried out according to European and National Regulations for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (facility license number C75-05-18). They complies also with internationally established principles of replacement, reduction and refinement in accordance with the Guide for the Care and Use of Laboratory animals (NRC 2011) and Guidelines for the Welfare and Use of Animals in Cancer Research [10 (link)].
The care and use of animals were carried out according to European and National Regulations for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (facility license number C75-05-18). They complies also with internationally established principles of replacement, reduction and refinement in accordance with the Guide for the Care and Use of Laboratory animals (NRC 2011) and Guidelines for the Welfare and Use of Animals in Cancer Research [10 (link)].
5
Orthotopic Transplantation of Breast Cancer Cells in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
2 × 106 MDA-MB-231 cells were orthotopically transplanted into the right fourth mammary gland of 8-wk-old Fox Chase CB17-SCID female mice (strain 236; Charles River). The cells were prepared as a mixture of 1 × 106 dox-inducible dsRed control cells and 1 × 106 dox-inducible eGFP NUP93 KD cells in 25 μl of DMEM containing 10% FBS, then mixed 1:1 with GFR Matrigel (354230; Corning). Mice were continuously treated with doxycycline (D9891; Sigma-Aldrich, 2 mg/ml in water containing 50 mg/ml sucrose) to induce expression of siRNA starting at the time of transplantation (“D0 dox”) or starting when tumors were palpable (10 d post-transplant, “D10 dox”). 4 wk after dox induction, the tumors were harvested and dissociated as previously described (Dravis et al, 2018) (link). Cell suspensions were stained with Brilliant Violet 421 anti-mouse CD45 (1:500, 103134; BioLegend), PE/Cy7 anti-human CD44 (1:500, 338816; BioLegend), and DAPI (1:1,000) and analyzed by flow cytometry. Analysis was carried out on an LSRII (Becton-Dickinson), and data were analyzed with FlowJo software.
6
Controlled Mouse Experiments at Salk
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All mouse experiments were performed with approval from the Animal Resources Department at the Salk Institute for Biological Studies and the Institutional Animal Care and Use Committee (IACUC), under the 2011–0005 approved protocol. CB17 SCID female mice were purchased from Charles River Laboratories. All mice were housed in a controlled environment, in a pathogen-free animal facility at the Salk Institute for Biological Studies, with a 12 h light-dark cycle at 23°C and 30–70% humidity, fed rodent chow ad libitum, and cared for by the Animal Research Department.
7
Xenograft Mouse Model Development
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All experimental procedures were approved by the Sanofi, Animal Care and Use committee. CD1 nude and CB17-SCID female mice were obtained from Charles River France. The mice (at least 7-week old at the start of engraftment) had free access to food and water.
8
SCID Mouse Model for Immunodeficiency Research
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Twelve-week-old old severe combined immunodeficient CB17 (SCID) female mice (n = 35) were purchased from Charles River Laboratories (Sulzfeld, Germany). The experimental animals were bred and obtained under specific pathogen-free conditions in Individually Ventilated Cages (Sealsafe Blue line IVC system, Techniplast, Akronom Ltd., Budapest, Hungary) with regulated ambient temperature and relative humidity maintained at 24 ± 2 °C and 55 ± 10%, respectively. A circadian light/dark cycle of 12 h was provided for the study mice. All animals were kept on sterile semi-synthetic rodent maintenance chow (Akronom Ltd., Budapest, Hungary) and sterile drinking water ad libitum.
All procedures applied followed the applicable sections of the Hungarian Laws as well as the animal welfare directions and regulations of the European Union. For the accomplishment of the present study, the permission of the Ethics Committee for Animal Experimentation of the University of Debrecen, Hungary (ethical permission number: 16/2022/DEMÁB) was granted. The fulfilment of the 3R policy was our priority.
All procedures applied followed the applicable sections of the Hungarian Laws as well as the animal welfare directions and regulations of the European Union. For the accomplishment of the present study, the permission of the Ethics Committee for Animal Experimentation of the University of Debrecen, Hungary (ethical permission number: 16/2022/DEMÁB) was granted. The fulfilment of the 3R policy was our priority.
9
Xenograft Tumor Studies with Veliparib and Cisplatin
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
C.B-17 SCID female mice were obtained from Charles River (Wilmington, MA) and used for all studies. A total of 2 × 106 viable A549-FP3 or Calu6-FP6 cells were inoculated subcutaneously into the right flank of female C.B-17 SCID mice on Day 0. The injection volume was 0.1 mL and was composed of a 1:1 mixture of S-MEM and matrigel. Tumors were size matched at ~250 mm3. Veliparib was synthesized at AbbVie (Abbott Park, IL) and formulated in 0.9% saline. Cisplatin was manufactured by Teva Parenteral Medicines, Inc. (Irvine, CA, USA) and was formulated in 0.9% saline. Cisplatin was dosed IV once at 6 mg/kg for preliminary efficacy experiments and at 4.5 mg/kg for the RNA-seq/concurrent efficacy study, while vehicle or veliparib were dosed orally at 200 mg/kg/day twice a day (BID) × 21 days for the preliminary efficacy study and once a day (QD) at 200 mg/kg/day × 21 days for the RNA-seq/concurrent efficacy study.
Tumor volume was calculated two times weekly for A549-FP3 efficacy studies and three times weekly for Calu6-FP6 efficacy studies and on the day of tumor harvest for RNA-seq studies. Tumor samples for the RNA-seq studies were collected at 24 hr, 48 hr, 72 hr, 10 days, and 21 days after cisplatin dosing. Mice were euthanized on the assigned harvest day for the RNA-seq studies or when tumor volume was ≤ 3000 mm3 or skin ulcerations occurred for efficacy studies.
Tumor volume was calculated two times weekly for A549-FP3 efficacy studies and three times weekly for Calu6-FP6 efficacy studies and on the day of tumor harvest for RNA-seq studies. Tumor samples for the RNA-seq studies were collected at 24 hr, 48 hr, 72 hr, 10 days, and 21 days after cisplatin dosing. Mice were euthanized on the assigned harvest day for the RNA-seq studies or when tumor volume was ≤ 3000 mm3 or skin ulcerations occurred for efficacy studies.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!